This is a repository copy of Liquid crystal nanoparticles for commercial drug delivery. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/119939/ Version: Accepted Version Article: Mo, J, Milleret, G and Nagaraj, M orcid.org/0000-0001-9713-1362 (2017) Liquid crystal nanoparticles for commercial drug delivery. Liquid Crystals Reviews, 5 (2). pp. 69-85. ISSN 2168-0396 https://doi.org/10.1080/21680396.2017.1361874 © 2017 Taylor & Francis. This is an Accepted Manuscript of an article published by Taylor & Francis in Liquid Crystals Reviews on 17 August 2017, available online: http://www.tandfonline.com/10.1080/21680396.2017.1361874. Uploaded in accordance with the publisher's self-archiving policy. Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing
[email protected] including the URL of the record and the reason for the withdrawal request.
[email protected] https://eprints.whiterose.ac.uk/ Liquid crystal nanoparticles for commercial drug delivery J. Moa G. Millereta and M. Nagaraja* a School of Physics and Astronomy, University of Leeds, Leeds LS2 9JT, UK
[email protected] 1 Liquid crystal nanoparticles for commercial drug delivery Liquid crystals are an intermediate state of matter that exists between conventional solids and liquids.